Core Viewpoint - The article discusses the recent approval of 10 innovative medical devices by the National Medical Products Administration (NMPA) in China, highlighting the advancements in the medical technology sector and the companies involved in these innovations [1]. Group 1: Innovative Medical Devices - The first product is a software for assessing chronic obstructive pulmonary disease, developed by Bojiang Life Sciences (Shanghai) Co., Ltd., which focuses on digital biomarkers and therapies for chronic disease management [2]. - The second product is an ultrasound therapy device from Shenzhen Tengfu Medical Technology Co., Ltd., which specializes in interventional devices for pulmonary embolism treatment [3]. - The third product is a transcatheter artificial tricuspid valve developed by Edwards Lifesciences, a leading company in structural heart disease devices [4][5]. - The fourth product is an ultrasound thrombolysis catheter and stent system from Shanghai Tengfu Medical Technology Co., Ltd., aimed at providing safer treatment options for venous thromboembolism [9][11]. - The fifth product is a radiation therapy planning software from Guoke Ion Medical Technology Co., Ltd., which focuses on the industrialization of medical heavy ion technology [12]. - The sixth product is an implantable cardioverter-defibrillator from Chuangling Heart Rhythm Management Medical Device (Shanghai) Co., Ltd., which aims to provide high-quality heart rhythm management products [13]. - The seventh product is a peripheral balloon-expandable stent system from Zhejiang Guichuang Medical Technology Co., Ltd., which specializes in high-end vascular interventional devices [14]. - The eighth product is a thoracoabdominal endoscopic surgical system from Intuitive Surgical, a global leader in robotic-assisted minimally invasive surgery [15][16]. - The ninth product is a coronary sinus balloon counterpulsation system from Shanghai Micron Melody Medical Technology Co., Ltd., which focuses on coronary intervention devices [17].

Core Viewpoint - Intuitive Surgical reported strong financial results for Q2 2025, with revenue of $2.44 billion, a 21.4% year-over-year increase, driven by the growth of surgical volumes and the accelerated adoption of the da Vinci 5 system, despite a subsequent decline in stock price due to concerns over cost structure and gross margin adjustments [1][3][4]. Revenue and Profit Performance - Total revenue for Q2 2025 reached $2.44 billion, up from $2.01 billion in Q2 2024, marking a 21.4% increase; GAAP net profit was $658 million (EPS of $1.81), a 25% increase year-over-year; non-GAAP adjusted net profit was $798 million, with an EPS of $2.19, exceeding analyst expectations by $0.26 [3][4]. Growth Drivers - The primary drivers of revenue improvement include the continuous growth in global surgical volumes and the increased installation of higher-end systems like the da Vinci 5 [4][5]. Da Vinci 5 System Performance - The da Vinci 5 system saw significant growth, with 395 new installations in Q2 2025, including 180 units of the da Vinci 5, compared to 70 units in the same period of 2024; the system has received regulatory approvals in the US, EU, and Japan for various minimally invasive procedures [6][7]. Market Expansion and Strategy - Intuitive Surgical is pursuing a strategy of direct market expansion, transitioning from distributors to direct operations, having integrated agents in Spain, Portugal, and Brazil in Q2 2025, enhancing brand control and training resource efficiency [11]. Surgical Volume Growth - Global surgical volumes using the da Vinci system grew by 17% year-over-year in Q2 2025, with an expected annual growth rate of 15.5%-17% for 2025, driven by the normalization of inpatient surgical demand in markets like the US, South Korea, India, and the UK [8][11]. Structural Advantages and Platform Ecosystem - Intuitive Surgical has established a robust growth moat through a platform ecosystem that integrates systems, consumables, and data, enhancing digital capabilities and deepening relationships with hospitals and physicians; the company continues to innovate with new indications and regional acquisitions [13][15].